{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:22:08Z","timestamp":1793658128069,"version":"4.5.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background and significance<\/jats:title>\n                    <jats:p>\n                      The interleukin-2 receptor gamma chain gene (\n                      <jats:italic>IL2RG<\/jats:italic>\n                      ) encodes for the common \u03b3 chain (\u03b3\n                      <jats:sub>c<\/jats:sub>\n                      ) protein, that is a shared signaling component of multiple interleukin receptors, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, and plays a pivotal role in lymphocyte development, homeostasis, and function. Mutations in\n                      <jats:italic>IL2RG<\/jats:italic>\n                      cause X-linked severe combined immunodeficiency (X-SCID) and a broad spectrum of related phenotypes ranging from typical SCID to leaky or atypical presentations, sometimes mimicking common variable immunodeficiency or immune dysregulation syndromes. Over the last decade (2015\u20132025), advances in molecular diagnostics, next-generation sequencing, and functional immunology have expanded the known\n                      <jats:italic>IL2RG<\/jats:italic>\n                      mutational spectrum and refined genotype\u2013phenotype correlations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent advances<\/jats:title>\n                    <jats:p>Recent research has uncovered novel hypomorphic variants, revealed the structural basis of receptor dysfunction, and elucidated the impact of specific mutations on JAK\u2013STAT signaling. Longitudinal natural history studies have improved understanding of disease progression in partial loss-of-function cases, while expanded newborn screening for SCID has facilitated earlier diagnosis. Advances in preclinical and clinical gene therapy have addressed historical challenges such as insertional mutagenesis, with emerging protocols achieving stable multilineage immune reconstitution. Moreover, comparative HSCT outcome analyses have informed donor selection, conditioning strategies, and post-transplant care, particularly in resource-limited settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Impact<\/jats:title>\n                    <jats:p>\n                      Improved molecular diagnostics have enabled precision diagnosis in patients with atypical presentations, allowing earlier initiation of curative therapies such as HSCT or gene therapy. Recognition of immune dysregulation, autoimmunity, and malignancy as part of the\n                      <jats:italic>IL2RG<\/jats:italic>\n                      -related spectrum has refined long-term follow-up protocols. Multidisciplinary care, integrating infectious disease, immunology, and genetics expertise, has become essential for optimizing patient outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Future Directions<\/jats:title>\n                    <jats:p>Ongoing priorities include the expansion of gene therapy trials to cover hypomorphic and late-presenting cases, refinement of reduced-intensity conditioning regimens to minimize toxicity, and development of targeted molecular therapies to modulate downstream signaling in non-transplant candidates. Global initiatives for SCID newborn screening, coupled with collaborative registries, are expected to improve early diagnosis and equitable access to curative interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1703097","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:26:39Z","timestamp":1773379599000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["IL2RG-related immunodeficiencies: from SCID to atypical presentations"],"prefix":"10.3389","volume":"17","author":[{"given":"Efrossini","family":"Briassouli","sequence":"first","affiliation":[{"name":"Second Department of Paediatrics, National and Kapodistrian University of Athens (NKUA), Aglaia Kyriakou Children\u2019s Hospital","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Marinakis","sequence":"additional","affiliation":[{"name":"Laboratory of Genetics, Department of Medicine, Democritus University of Thrace","place":["Alexandroupolis, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vana","family":"Spoulou","sequence":"additional","affiliation":[{"name":"First Department of Paediatrics & Immunobiology & Vaccinology Research Lab, National and Kapodistrian University of Athens, \u201cAgia Sophia\u201d Children\u2019s Hospital of Athens","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi D.","family":"Notarangelo","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028449","article-title":"The common cytokine receptor \u03b3 Chain family of cytokines","volume":"10","author":"Lin","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.017","article-title":"Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006\u20132014 European cohort","volume":"149","author":"Lankester","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00745-2","article-title":"Novel hemizygous IL2RG p.(Pro58Ser) mutation impairs IL-2 receptor complex expression on lymphocytes causing X-linked combined immunodeficiency","volume":"40","author":"Tuovinen","year":"2020","journal-title":"J Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13223-018-0317-y","article-title":"IL2RG hypomorphic mutation: identification of a novel pathogenic mutation in exon 8 and a review of the literature","volume":"15","author":"Lim","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.028","article-title":"The \u03b3c family of cytokines: basic biology to therapeutic ramifications","volume":"50","author":"Leonard","year":"2019","journal-title":"Immunity"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-015-2062-4","article-title":"The common \u03b3-chain cytokine receptor: tricks-and-treats for T cells","volume":"73","author":"Waickman","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"B8","unstructured":"Common cytokine receptor gamma-chain family signaling pathways"},{"key":"B9","unstructured":"IL2RG binds JAK3"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020066","article-title":"Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells","volume":"195","author":"Tan","year":"2002","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80566-X","article-title":"Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis","volume":"8","author":"Refaeli","year":"1998","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-362533","article-title":"IL-21 is the primary common \u03b3 chain-binding cytokine required for human B-cell differentiation in vivo","author":"Recher","year":"2011","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1847","article-title":"Transplacentally acquired maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients","volume":"98","author":"M\u00fcller","year":"2001","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4103\/0256-4947.62834","article-title":"Delayed presentation of severe combined immunodeficiency due to prolonged maternal T cell engraftment","volume":"30","author":"Al-Muhsen","year":"2010","journal-title":"Ann Saudi Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.04.049","article-title":"Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency","volume":"139","author":"Wahlstrom","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70207-6","article-title":"Engrafted maternal T cells in human severe combined immunodeficiency: evidence for a TH2 phenotype and a potential role of apoptosis on the restriction of T-cell receptor variable beta repertoire","volume":"101","author":"Plebani","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.01.004","article-title":"Maternal T-cell engraftment impedes with diagnosis of a SCID-ADA patient","volume":"193","author":"Lanfranchi","year":"2018","journal-title":"Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"261470","DOI":"10.1155\/2012\/261470","article-title":"Characterizing T cells in SCID patients presenting with reactive or residual T lymphocytes","volume":"2012","author":"Lev","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqv079","article-title":"Maternal T-cell engraftment interferes with human leukocyte antigen typing in severe combined immunodeficiency","volume":"145","author":"Liu","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.08.022","article-title":"Maternofetal transfusion, maternal chimerism, and maternal engraftment: A mystery in health and disease","author":"Cagdas","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3892\/ijmm.2023.5228","article-title":"Exhaustion\u2212like dysfunction of T and NKT cells in an X\u2212linked severe combined immunodeficiency patient with maternal engraftment by single\u2212cell analysis","volume":"51","author":"Dong","year":"2023","journal-title":"Int J Mol Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.09.044","article-title":"ESTABLISHING DIAGNOSTIC CRITERIA FOR SCID, LEAKY SCID, AND OMENN SYNDROME: THE PRIMARY IMMUNE DEFICIENCY TREATMENT CONSORTIUM EXPERIENCE","volume":"133","author":"Shearer","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/genes13010035","article-title":"Somatic reversion of a novel IL2RG mutation resulting in atypical X-linked combined immunodeficiency","volume":"13","author":"Hou","year":"2021","journal-title":"Genes (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-015-0174-0","article-title":"IL2RG reversion event in a common lymphoid progenitor leads to delayed diagnosis and milder phenotype","volume":"35","author":"Hsu","year":"2015","journal-title":"J Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.696350","article-title":"Case report: interleukin-2 receptor common gamma chain defect presented as a hyper-igE syndrome","volume":"12","author":"Belaid","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01908","article-title":"Clinical, immunological, and molecular features of typical and atypical severe combined immunodeficiency: report of the italian primary immunodeficiency network","volume":"10","author":"Cirillo","year":"2019","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.09.037","article-title":"Omenn syndrome: inflammation in leaky severe combined immunodeficiency","volume":"122","author":"Villa","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149708","article-title":"Detection of T lymphocytes with a second-site mutation in skin lesions of atypical X-linked severe combined immunodeficiency mimicking Omenn syndrome","volume":"112","author":"Wada","year":"2008","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2025.02.11.25322033","DOI":"10.1101\/2025.02.11.25322033","article-title":"The ClinGen Severe Combined Immunodeficiency Disease Variant Curation Expert Panel: Specifications for classification of variants in ADA, DCLRE1C, IL2RG, IL7R, JAK3, RAG1, and RAG2","author":"Jacovas","year":"2025","journal-title":"medRxiv"},{"key":"B32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.alit.2017.06.003","article-title":"Flow cytometry-based diagnosis of primary immunodeficiency diseases","volume":"67","author":"Kanegane","year":"2018","journal-title":"Allergology Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.08.049","article-title":"Common variable immunodeficiency and natural killer cell lymphopenia caused by Ets-binding site mutation in the IL-2 receptor \u03b3 (IL2RG) gene promoter","volume":"137","author":"Chandra","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.alit.2017.06.003","article-title":"Flow cytometry-based diagnosis of primary immunodeficiency diseases","volume":"67","author":"Kanegane","year":"2018","journal-title":"Allergology Int"},{"key":"B35","unstructured":"Australasian society of clinical immunology and allergy (ASCIA)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.024","article-title":"Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency","volume":"143","author":"Kohn","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867753","article-title":"Features of hemophagocytic lymphohistiocytosis in infants with severe combined immunodeficiency: our experience from chandigarh, north India","volume":"13","author":"Vignesh","year":"2022","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1381558","article-title":"Long term outcomes of severe combined immunodeficiency: therapy implications","volume":"13","author":"Heimall","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00731-6","article-title":"Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium","volume":"402","author":"Thakar","year":"2023","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-840702","article-title":"SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery","volume":"132","author":"Haddad","year":"2018","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-362533","article-title":"IL-21 is the primary common \u03b3 chain-binding cytokine required for human B-cell differentiation in vivo","volume":"118","author":"Recher","year":"2011","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-809822","article-title":"B-cell differentiation and IL-21 response in IL2RG\/JAK3 SCID patients after hematopoietic stem cell transplantation","volume":"131","author":"Miggelbrink","year":"2018","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.055","article-title":"Gene therapy for X-linked severe combined immunodeficiency: Historical outcomes and current status","volume":"146","author":"Pai","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.09.027","article-title":"Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study","volume":"153","author":"Eissa","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.822","article-title":"Late-onset enteric virus infection associated with hepatitis (EVAH) in transplanted SCID patients","volume":"151","author":"Riller","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41577-022-00800-6","article-title":"Gene therapy for inborn errors of immunity: past, present and future","volume":"23","author":"Fischer","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200301163480314","article-title":"A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency","volume":"348","author":"Hacein-Bey-Abina","year":"2003","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified \u03b3-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02208-8","article-title":"Access to gene therapy for rare diseases when commercialization is not fit for purpose","volume":"29","author":"Fox","year":"2023","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"eaan0820","DOI":"10.1126\/scitranslmed.aan0820","article-title":"Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1","volume":"9","author":"Schiroli","year":"2017","journal-title":"Sci Transl Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/s41467-019-09614-y","article-title":"Gene correction for SCID-X1 in long-term hematopoietic stem cells","volume":"10","author":"Pavel-Dinu","year":"2019","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1067417","article-title":"CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells","volume":"13","author":"Brault","year":"2022","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1839148","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1703097\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T12:18:07Z","timestamp":1776946687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1703097\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2026.1703097"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1703097","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1703097"}}